How We Lead – Perspectives from Two Key Biotechnology Hubs in North America

March 8, 2021 11:30 AM - 1:15 PM

Webinar, click "live-stream" button to view

Add to Calendar 3/8/2021 11:30:00 AM 3/8/2021 1:15:00 PM How We Lead – Perspectives from Two Key Biotechnology Hubs in North America

Join us on International Women’s Day, March 8, 2021, when WIB-Greater Montreal and WIB-Greater Boston will present a joint event with BIOQuébec and MassBio.

BIOQuébec is committed to supporting Québec’s biotechnology and life sciences industry. MassBio’s mission is to advance Massachusetts’ leadership in the life sciences and each is dedicated to improving healthcare and quality of life. Join the discussion of the landscape in Quebec and Massachusetts and biotech leaders’ perspectives on challenges/obstacles faced, leadership styles, where do we want to be, and how do we get there.

The event will be facilitated by journalist-columnist Tasha Kheiriddin with panelists from Québec: Anie Perrault, executive director BIOQuébec, Clarissa Desjardins, founder and former CEO, Clementia (now Ipsen), and Nadine Beauger, President & CEO, IRICOR and from Massachusetts: Kendalle Burin O’Connell, President & COO MassBio, Ramani Varanasi- President & CEO of X-Biotix Therapeutics, and Liang Schweizer- CEO & CSO of HiFiBiO Therapeutics.

PLEASE NOTE: You will be redirected to the Women In Bio event page by clicking, "Register Now." This event requires you to sign-in to receive a personalized link to the webinar. Please select “sign-in” and then choose “non-member.” The event is free for all MassBio members.

Disclaimer: This event may be recorded. There is a possibility your image and/or voice may be a part of that recording. If you are uncomfortable, please be sure to turn off your webcam.

 Webinar, click "live-stream" button to view
President and Chief Executive Officer, IRICoR
---Dr. Nadine Beauger is President and CEO of IRICoR, a Centre of Excellence in Commercialization and Research specializing in drug discovery, based at IRIC/University of Montreal. Under her leadership, IRICoR has expanded its project portfolio across Quebec and the rest of Canada. IRICoR provides academics with its tailor-made funding and support towards increasing their projects’ value and establishing strong partnerships with the private sector for innovative therapeutic solutions to reach patients faster. Before this appointment, Dr. Beauger was Vice-President - Scientific Liaison at that same organization that she joined in 2009. She was instrumental at building IRICoR’s project portfolio and related intellectual property (IP) practice and strategy, which have led to successful licensing agreements and partnerships with industry. She had brought to IRICoR over 15 years of experience in technology assessment and transfer, venture capital, IP and project portfolio management, due diligence, and research with thorough experience in both the private and the academic sectors, namely at Robic, a Montreal-based IP boutique; VantagePoint Venture Partners, a leading California-headquartered venture capital firm; and Paladin Labs Inc, a top specialty pharmaceutical company based in Montreal. She holds a Ph.D. in Biomedical Sciences (Hematology and Oncology), an M.Sc. in Cellular Biopathology from Université de Montréal, a B.Sc. in Anatomy from McGill University and an MBA degree from HEC Montréal (Excellence Studentship Award and Best Speaker Award). Dr. Beauger is a Board member of CHU Ste-Justine Foundation, ExCellThera, one of IRICoR’s spin-off companies and Immune BioSolutions, a Sherbrooke-based innovative biotech specialized in antibody production.